Sirolimus-FKBP12.6 Impairs Endothelial Barrier Function through PKCα Activation and Disruption of the p120-VE Cadherin Interaction

OBJECTIVE: Sirolimus (SRL) is an immunosuppressant drug used to prevent rejection in organ transplantation and neointimal hyperplasia when delivered from drug eluting stents (DES). Major side effects of SRL include edema and local collection of intimal lipid deposits at the DES site suggesting that...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Habib, Anwer, Karmali, Vinit, Polavarapu, Rohini, Akahori, Hirokuni, Cheng, Qi, Pachura, Kim, Kolodgie, Frank D., Finn, Aloke V.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3827918/
https://ncbi.nlm.nih.gov/pubmed/23887639
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/ATVBAHA.113.301659
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados